Marisol Aldana, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 200 Marriott Dr, Portland, TX 78374 Phone: 361-777-3991 |
Kellie Lyn Underwood, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 401 Northshore Blvd, Portland, TX 78374 Phone: 361-643-3777 Fax: 361-643-3777 |
Jimmy Anthony Canales Ii, COTA Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 221 Cedar Dr, Portland, TX 78374 Phone: 361-643-1888 |
Blooming Buds Therapy Llc Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1004 Starlite Dr, Portland, TX 78374 Phone: 361-960-5740 |
Ulysses G Cabanog, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 401 Northshore Blvd, Portland, TX 78374 Phone: 361-777-0303 |
News Archive
In a recently published study in the journal Genome Research, a team of scientists led by Dr. Shaying Zhao at the University of Georgia have developed a novel cross-species comparative genomics and oncology strategy for cancer driver gene discovery, using microarray technologies from Roche NimbleGen, that differs fundamentally from current approaches which focus on human cancers only.
In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers.
Nanogen, Inc. has announced that it has delivered the second phase milestone requirements, including the point-of-care prototype device to detect influenza viruses rapidly in clinical samples, to the Center for Disease Control and Prevention (CDC) for their evaluation.
Researchers simulating conditions of reduced cabin pressure and reduced oxygen levels, such as may be encountered during an 8-hour aeroplane flight, found no increase in the activation of the blood clotting system among healthy individuals
CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, in Russia at the State Budgetary Healthcare Institution of Sverdlovsk Region - Sverdlovsk Regional Oncology Center in Ekaterinburg, Russia.
› Verified 9 days ago